
@article{wu2025,
	title = {The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial},
	author = {Wu, J. and Pei, F. and Zhou, L. and Li, W. and Sun, R. and Li, Y. and Wang, Z. and He, Z. and Zhang, X. and Jin, X. and Long, Y. and Cui, W. and Wang, C. and Chen, E. and Zeng, J. and Yan, J. and Lin, Q. and Zhou, F. and Huang, L. and Shang, Y. and Duan, M. and Zheng, W. and Zhu, D. and Kou, Q. and Zhang, S. and Liu, Y. and Yao, C. and Shang, M. and Peng, S. and Zhou, Q. and Cheng, K.K. and Guan, X.},
	year = {2025},
	date = {2025},
	journal = {BMJ},
	doi = {10.1136/bmj-2024-082583},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85215926316&doi=10.1136%2fbmj-2024-082583&partnerID=40&md5=b8e085b4a38e2e016d266d235cb8c56b},
	note = {TLDR: This trial found no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality in adults with sepsis, and a potential differential effect of thymosin α1 on the primary outcome based on age.}
}
